Expert Viewpoints
Expert Viewpoint November 2009
Ian Flinn, MD, PhD, discusses the clinical status of PI3K-targeted agents in hematologic malignancies and solid tumors.
Howard Liebman, MD, reviews current thinking regarding idiopathic thrombocytopenic purpura, including studies presented at the 2008 hematology meeting.
Hugo R. Rosen, MD, discusses recent advances in the treatment of hepatocellular carcinoma including local ablative therapies and liver transplantation.
Bart L. Scott, MD, MS, from the Fred Hutchinson Cancer Research Center, summarizes the current status of hypomethylating agents for the treatment of myelodysplastic syndromes.
Matti S. Aapro, MD, discusses the European perspective on the use of ESAs in oncology patients.
Rafael Fonseca, MD, explores the impact of lenalidomide and bortezomib in the frontline treatment of multiple myeloma.
Al B. Benson III, MD, discusses the predictive implications of KRAS status with regard to the use of anti-EGFR agents in the treatment of colorectal cancer.
Nicholas J. Robert, MD, discusses the impact of the results of the second interim analysis from the BCIRG 006 trial that were presented at the 2006 San Antonio Breast Cancer Symposium.
In this Expert Viewpoint, John M. Kirkwood, MD, reviews the latest data in melanoma with a focus on presentations delivered at the 2006 annual meeting of the American Society of Clinical Oncology.
Lee Rosen, MD, discusses provocative new findings presented at the 2006 meeting of the American Association of Cancer Research.
Edward Chu, MD, briefly reviews current data and future directions in the use of the oral fluoropyrimidine capecitabine for the treatment of advanced colorectal cancer.
Mark A. Socinski, MD, comments on recent data confirming the benefit of adjuvant therapy after curative resection in early-stage non–small-cell lung cancer.
Charles Vogel, MD, discusses new guidelines regarding use of myeloid growth factor support and their implications for clinical practice.
Carol Moreno, MD and Emili Montserrat, MD discuss the implications of achieving MRD-negative status in CLL using recent treatment strategies.
Robert Motzer, MD, reviews new data from ASCO on multiple agents that demonstrate unprecedented activity in renal cell carcinoma.
Edith A. Perez, MD, describes new data that may mandate an immediate change in the way clinicians manage patients with HER2-positive breast cancer.
E. David Crawford, MD, sheds light on testosterone replacement therapy and cancer risk.
Fran Castellow, MSEd, and Roy A. Beveridge, MD, discuss the benefits of patient assistance programs and how they can help oncology patients.
Douglas W. Blaney, MD, discusses preliminary results regarding bisphosphonates and pegfilgrastim as supportive therapy in breast cancer and myeloma
William J. Gradishar, MD, Chair of the recent Lynn Sage Breast Cancer Symposium in Chicago, Illinois, discusses the highlights of the meeting.
John L. Marshall, MD, describes the process of selecting from among the recently available treatment options for colorectal cancer
Donald I. Feinstein, MD, discusses the findings of 2 trials evaluating desmopressin acetate (DDAVP) in patients with von Willebrand disease
Paul M. Harari, MD, and Prakash Chinnaiyan, MD, discuss important findings regarding the treatment of head and neck cancer presented at this year's American Society of Clinical Oncology meeting
Hope Rugo, MD, talks about recent findings and upcoming studies regarding capecitabine
Donald I. Feinstein, MD, discusses the potential use of low-dose aspirin to prevent thrombotic complications in patients with polycythemia rubra vera who have normal platelet counts and no history of thrombosis
Clifford Hudis, MD, discusses the clinical implications of a study showing that treatment with letrozole after the first 5 years following surgery was associated with a reduced risk of breast cancer recurrence
Alexandra M. Levine, MD, reviews recent data on therapeutic regimens and the role of concomitant HAART in patients with AIDS-related lymphoma
|